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Abstract
Background: Steroid associated osteonecrosis is difficult to treat. Teriparatide, as the only one bone anabolic drug,
has achieved very promising effect in osteoporosis and other bone skeletal diseases. We carried out this animal
study to evaluate the effect of subcutaneous injection of teriparatide for the steroid induced femoral head necrosis
in a rat model.
Methods: 24 Sprague–Dawley male adult rats were included in the study. All the rats were randomized into 4
groups: 18 rats from LPS/MPS group, LPS/MPS + PTH group and LPS/MPS + NS group were given lipopolysaccharide
(20 μg/kg) and methylprednisolone (40 mg/kg) to establish the steroid induced osteonecrosis model. 6 rats from
NS group only received normal saline. 4 weeks later, All the rats in LPS/MPS group and NS group were sacrificed
and the femoral heads were harvested. After that, the 6 rats in the LPS/MPS + PTH group received subcutaneous
injection of 20 μg/kg teriparatide and LPS/MPS + NS group only received equal amount of normal saline. After
4 weeks, the serum bone marker was tested and the femoral head were harvested. Micro-CT and histological
examination were performed to compare the incidence of osteonecrosis and trabeculae parameters for the
femoral head.
Results: At 4 weeks, rats in LPS/MPS group showed significant osteonecrosis by histological examination (83.3 %)
which suggested successful steroid induced osteronecrosis animal models were established. After the treatment of
4 weeks, the LPS/MPS + PTH group showed significant lower incidence rate of osteonecrosis compared with the
LPS/MPS + NS group (16.7 % vs.75 %, P < 0.05). The micro CT examination showed higher bone volume/total volume,
trabecula thickness and bone mineral density in the LPS/MPS + PTH group compared with the LPS/MPS + NS group.
The serum osteocalcin was a little higher in the LPS/MPS + PTH group (4.54 ± 1.61vs.3.58 ± 1.81, P = 0.358), but it didn’t
reach a statistical significance.
Conclusions: Systemic application of teriparatide for steroid induced osteonecrosis in rats showed a beneficial effect.
This may be one promising therapy for early stage osteonecrosis.
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Background
Osteonecrosis of the femoral head was a side effect of the
corticosteroid in treating autoimmune and other diseases.
High-dose corticosteroid administration was considered
to be the most common risk factor for osteonecrosis [1].
The progression of osteonecrosis would ultimately lead to
collapse of the femoral head when femoral head or total
hip replacement was usually required. Osteonecrosis was
responsible for 10 % of all total hip replacement surgeries
and was the most common cause of total hip replacement
in young adults; but problems with infection, osteolysis,
dislocation and revisions were worse with total hip re-
placement for steroid-induced osteonecrosis than for
osteoarthritis [2]. Lots of conservative therapy including
anticoagulants, bisphosphonates and statins had been
tried on the early stage femoral head necrosis [3–5], but
there was still no satisfactory resolution.
Teriparatide (rhPTH[1–34]) was a bone anabolic agent
which was approved to treat osteoporosis both in women
and men [6]. In vitro studies had shown that teriparatide
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stimulated new bone formation by increasing osteoblast
number, enhancing osteogenic differentiation of bone
mesenchymal stem cell and improving cell survival [7].
Besides osteoporosis, teriparatide had emerged as a poten-
tial curative drug in promoting spinal fusion [8], bone
fracture healing [9] and biphosphates associatedosteone-
crosis of the jaw [10]. One of the pathogenesis of femoral
head necrosis was that the steroid suppressed the activity
of the bone mesenchymal stem cell and decreased the
osteogenic differentiation [11]. So we hypothesized the
teriparatide might treat the steroid induced femoral head




The experiment was performed under the approval of the
Animal Experimentation Ethics Committee of Peking
Union Medical College Hospital. Twenty-four Sprague–
Dawley male adult rats (age for 12 weeks; body weight for
400–450 g) were used in this study. The SD rats were
bought from Charles River Company (Beijing, China). All
rats were housed in pairs in custom-designed plexiglas
cages (50 × 35 × 20 cm) under standard laboratory condi-
tions (12/12-h light/dark cycle, 24-25 °C, humidity with
50-55 %) and allowed freely access to food and water dur-
ing the study.
Grouping and animal model establishment
All the rats were randomized into 4 groups: NS group,
LPS/MPS group, LPS/MPS + PTH group, LPS/MPS +NS
group.(see Fig. 1).18 rats from the latter three groups
were given two doses intraperitoneal injection of 20 μg/kg
of lipopolysaccharide (LPS, Escherichia coli 055:B5, Sigma,
St. Louis, MO, USA) on days 0 and 1 at a time interval of
24 h, 24 h later, the eighteen rats received three intra-
muscular injection of 40 mg/kg methylprednisolone
Sodium Succinate (Pfizer Pharmaceutical, China) on
days 3, 4 and 5 at a time interval of 24 h. 6 rats from NS
group only received normal saline. 4 weeks later, All the
rats in LPS/MPS group and NS group were sacrificed and
the femoral heads were harvested. The femurs were decal-
cified and stained with HE. The successful osteonecrosis
animal model was confirmed by histological examination.
The twelve rest rats in the LPS/MPS + PTH group and
the LPS/MPS +NS group would continue to be kept
under the same condition. The former group received
20 μg/kg of teriparatide (Lilly, Indianapolis, USA) sub-
cutaneous injection everyday, while the latter group
received normal saline. After four weeks, the blood sam-
ples were collected from the inferior vena cava with the
animals in a fasting state. Then, the rats were sacrificed
with an overdose of pentobarbital sodium (240 mg/kg ip)
and bilateral femurs were harvested.
Serum osteocalcin examination
The serum of the rat blood was collected by centrifuga-
tion at 3000 rpm for 10 min at 4 °C and stored at −80 °
C until examination. Serum osteocalcin was measured
by ELISA using a kit from SenXiong Technologies In-
corporated (Shanghai, China). This protocol adopted the
method of double antibody sandwich ABC-ELISA. With
anti-rat Osteocalcin monoclonal antibody coated on the
ELISA plate, anti-rat Osteocalcin biotinylated antibody
was added, and immune complexes would connected to
the board. Streptavidin labeled with horseradish peroxid-
ase would bind to biotin, then enzyme substrate TMB
was added, it would turn blue, then stopping solution of
sulfuric acid was added, the color would turn yellow. Fi-
nally the OD value was measured at 450 nm. As the rat
Osteocalcin concentrations was proportional to the OD
value, the osteocalcin concentration in rat specimens
could be obtained by drawing standard curve. Each spe-
cimen would be repeated for three times.
Micro CT scan and quantitative analysis
The femur specimens were sampled and fixed in 10 %
buffered neutral formalin solution until examination.
The specimens were scanned by Inveon micro PET/CT
manufactured by Siemens (Berlin, Germany) at a voltage
of 60 kV and a current of 400uA, with entire scan length
of 20 mm in a spatial resolution of 10 μm used for
animal experimental studies and reconstructed using
Inveon analysis workstation. The micro CT diagnosis
standard for femoral head necrosis is fracture of the tra-
becula, cyst degeneration, sclerosis band or flattened
shape of the femoral head. Two independent researchers
made the diagnosis blindedly, if there was disagreement,
consensus was reached by a third person. 1 mm below
the center of the epiphyseal line with a total of 50 slices
was chosen as the region of interest (ROI) for the ana-
lysis and comparison of trabecula paramenters. On the
cross-section the cortical bone and spongy bone was
separated manually by auto trace, later the trabeculae
and the bone marrow was separated by the threshold
function (Fig. 2). After that, the bone volume/total volu-
me(BV/TV), bone surface area/bone volume, trabecular
thickness, trabecular number, Trabecular spacing, tra-
becular pattern factor, cortical wall thickness and bone
mineral density (BMD) in the ROI were computed re-
spectively by the workstation.
Histopathology
The femur specimens were fixed in 10 % buffered
neutral formalin solution for 72 h and followed by decal-
cification with 10 % ethylenediaminetetraacetic acid
(EDTA)- 0.1 M phosphate buffer (pH 7.4). After decalci-
fication, the tissues were dehydrated in graded ethanol,
embedded in paraffin, cut into 4 μm thick sections in
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the coronal plane, processed for routine hematoxylin
and stained by eosin for the evaluation of osteonecrosis.
All sections were assessed blindly by two independent
authors using a microscope (Leica, Wetzlar, Germany),
the diagnosis of osteonecrosis was established based on
the presence of empty lacunae or pyknotic nuclei of
osteocytes in the bone trabeculae, accompanied by sur-
rounding bone marrow cell necrosis [12]. If the diagno-
sis differed between the two examiners, a consensus was
reached by a third person.
Statistical analysis
The Student’s t test or Fisher’s Exact test was performed
to compare the variables between the two groups. The
parameters were expressed as Mean ± SD. Statistical ana-
lysis was performed using SPSS for Windows (Version




All rats were survived during the experimental period.
The histopathological appearance of the femoral head was
given in Fig. 3. The empty bone lacuna and broken of the
trabeculae were obvious in the LPS/MPS group. The inci-
dence of osteonerosis at 4 weeks was 83.3 %(10/12) in the
LPS/MPS group and 0(0/12) in the NS group by the
standard of HE stained histological examination.(P < 0.05)
Fig. 2 The region of interest chosen and the identification of trabecula
Fig. 1 The flow diagram of the study
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which suggested a successful animal model of steroid in-
duced femoral head necrosis was established. By the HE
stained histological examination, the incidence of osteo-
necrosis was 75 %(9/12) in the LPS/MPS +NS group and
16.7 %(2/12) in the LPS/MPS + PTH group at 8 weeks.
(P < 0.05) The incidence of osteonerosis of LPS/MPS +
PTH group was significantly lower than the LPS/MPS +NS
group.(see Table 1). Morover, the histopathological examin-
ation showed that the trabeculae in the LPS/MPS + PTH
group was condense and well arranged while the trabeculae
in the LPS/MPS +NS group was thin and disorderly.
Serum osteocalcin
The serum osteocalcin showed a little higher in the LPS/
MPS + PTH group than the LPS/MPS +NS group, however,
the result didn’t reach a statistical significance (Table 2).
Micro CT scan and quantitative analysis
By the standard of microCT, the incidence of osteo-
necrosis was 58.3 %(7/12) and 0(0/12) in the LPS/MPS
group and NS group respectively (P < 0.05). At 8 weeks,
the incidence of osteonecrosis was 50 %(6/12) in the
LPS/MPS +NS group and 0(0/12) in the LPS/MPS +
PTH group(P < 0.05). The incidence of osteonerosis of
Fig. 3 The histopathological appearance of the femoral head. a was from NS group which showed well arranged trabecula and normal osteocyte with
nuclei. The red arrow demonstrates the normal bone marrow. b, c and d were from LPS/MPS group which showed empty bone lacuna, bone marrow
necrosis, and broken trabecula. The blue arrow in b demonstrateds the empty bone lacuna. The black arrow in c demonstrates the necrosis of the bone
marrow. The yellow arrow in d demonstrates the broken of the trabecula. At 8 weeks, E from LPS/MPS +NS group showed broken of the trabeculae.
f was from LPS/MPS + PTH group which showed better arranged and more condense trabeculae compared with E.(HE stained; magnification,×100)
Table 1 Incidence of osteonecrosis(%)
Group Week 4 HE Week4 CT Week 8 HE Week8 CT
LPS/MPS group 83.3(10/12) 58.3(7/12) NA NA
NS group 0(0/12) 0(0/12) NA NA
LPS/MPS + PTH group NA NA 16.7(2/12) 0(0/12)
LPS/MPS + NS group NA NA 75(9/12) 50(6/12)
P value 0.000 0.005 0.012 0.014
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LPS/MPS + PTH group was significantly lower than the
LPS/MPS +NS group.(see Table 1). Representative micro
CT images of osteonerosis were given in Fig. 4.
The quantitative analysis of the trabeculae showed that
bone volume/total volume, trabecula thickness and bone
mineral density were significantly higher in the LPS/
MPS + PTH group (Table 3).
Discussion
Steroid induced femoral head necrosis was refractory
and most of the patients would undergo collapse of the
femoral head and had to receive total hip arthoplasty.
Many researchers have tried biphosphates, anticoagulant
and statins [3–5]. However, there is still no ideal resulo-
tion for the early staged osteonecrosis. Some researchers
have described abnormalities in the number or in the
function of bone progenitor cells in osteonecrosis [11, 13].
The hypothesis that osteonecrosis could be related to a
mechanism that results in an imbalance between osteo-
blast formation and necrosis developed.[14, 15] Moreover,
the osteogenic differentiation of the mesenchymal stem
cell was also attenuated by glucocorticoids [16, 17].
In the present study, the steroid-induced osteonecrosis
model was established in rats by two injections of low-
dose LPS(20ug/Kg) combined with three subsequent
injections of high-dose MPS(40 mg/Kg) . The most clas-
sical animal model for osteonerosis was rabbit and there
were two classical inductive protocols commonly used
for establishing ON relevant to steroid. One was to use a
single injection of high-dose methylprednisolone (MPS)
(20 mg/kg), however, the incidence was as low as
43 %[18]. The other was to use two injections of high-
dose lipopolysaccharide (LPS,100ug/Kg) combined with
subsequent three injections of high-dose MPS (20 mg/Kg),
which induced higher ON incidence (85 %) but accom-
panied with high mortality of experimental animals (50 %)
[19]. Qin et al. applied one intravenous injection of LPS
(10 μg/kg) and three injections of 20 mg/kg of MPS. He
reported 93 % of the rabbits (13/14) developed ON and no













mean ± SD 3.58 ± 1.81 4.54 ± 1.61 −0.96 0.358
Fig. 4 The coronal section of the femoral head. a was from NS group. b was from LPS/MPS group. c was from LPS/MPS + PTH D was from
LPS/MPS + NS group. Obvious necrosis and cyst degeneration could be seen in the b and d(red arrow). In the LPS/MPS + PTH, no significant
osteonecrosis lesion was seen
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rabbits died throughout the experiment period [20]. Rats
were the second common animal osteonecrosis model.
Okazaki et al. gave male Wistar rats two injections of
2 mg/kg LPS and three injections of 20 mg/kg methyl-
prednisolone. The incidence of osteonerosis were 67 %
at three weeks and 33 % at four weeks. However, the
number of the animal was too limited [21]. Tong P et al.
applied a dose of 20ug/kg LPS via daily i.p. administra-
tion for two times and three injections of methylpred-
nisolone (40 mg/kg). They reported osteonecrosis was
observed in seven of ten rats (70 %) [22]. We adopted the
method described by Tong P et al. and the incidence
of location-specific femoral head necrosis was 83.3 %
(10/12) by histological examination. With the standard of
microCT, the incidence of femoral head necrosis was
58.3 %(7/12), which was lower than the histological exam-
ination. The reason may be that the necrosis of the osteo-
blast and bone marrow couldn’t be displayed in micro CT
images. The histopathology of osteonecrosis in this model
was characterized by empty lacunae or pyknotic nuclei
of osteocytes accompanied by surrounding bone marrow
cell necrosis and the micro CT images of femoral head
necrosis were fracture of the trabeculae, cyst degeneration,
sclerosis band or flattened shape of the femoral head,
which were similar to osteonecrosis in steroid-treated pa-
tients. However, osteonecrosis often lead to femoral head
collapse in human but not rats, as the epiphyseal line of
the femur was permanent in adult rats but not in adult
human. What’s more, false negative results may exist with
micro CT diagnosis as the early staged osteonecrosis can’t
be displayed. This could explain why the incidence of
osteoncrosis by CT was lower than that of histology. In
our study, the incidence of osteonecrosis in the LPS/MPS
group was 83.3 %(10/12), and no rats died during the
whole period, indicating that this rat model was safe
and reliable. Therefore, this animal model was reliable for
evaluating the intervention of steroid-induced osteonero-
sis studies.
Teriparatide (rhPTH [1–34]) was an amino-terminal
fragment of PTH which had been shown to stimulate new
bone formation by increasing osteoblast activity and num-
bers by inducing the mesenchymal stem cell osteogenic
differentiation [23]. It was the only anabolic agent currently
approved for the treatment of post-menopausal osteopor-
osis, idiopathic or hypogonadal osteoporosis in men, and
steroid-induced osteoporosis [24, 25]. Teriparatide induced
new bone formation at inactive bone surfaces and further
stimulated mineral apposition at active remodeling sur-
faces, resulting in increased bone mass trabecular thick-
ness, and improved trabecular connectivity in animals and
patients. Histologic studies had shown that the increase in
bone formation was largely due to an increase in the num-
ber of matrix-synthesizing osteoblasts [26]. Increased os-
teoblastogenesis, attenuation of osteoblast apoptosis and
activation of quiescent lining cells had been proposed as
explanations for this effect of PTH.
A great number of studies had shown that the teri-
paratide had the potential effect in bone union, spinal
fusion and bone defect repair [27, 28]. Moreover, teri-
paratide also had been shown to be useful in periodontal
disease. In a trial where 40 adults with chronic peri-
odontitis were subjected to periodontal surgery and teri-
paratide, it resulted in greater radiographic resolution of
the periodontal bone defects compared to placebo with
accelerated osseous wound healing in the oral cavity
[29]. Osteonecrosis of jaw (ONJ) involved necrotic, ex-
posing bone in the jaw, pain and swelling associated with
long-term bisphosphonate use. The precise mechanism
underlying the development of ONJ with bisphosphonate
use was still not clear. Teriparatide has been reported to
be an potential treatment option for ONJ [10]. As teri-
paratide promotes osteoblast differentiation and activity, it
might be beneficial to promote bone formation and necro-
sis lesion repair.
The pathogenesis of the femoral head necrosis was
that the activity of MSC as well as the osteogenic differ-
entiation potential was attenuated by the steroids, appli-
cation of teriparatide might increase the MSC activity
and osteogenic differentiation, thus reverse the effect of
steroids in osteonecrosis repair process. Moreover, the
trabeculae parameters by micro CT showed that tera-
paratide also increased the bone volume, trabeculae
thickness and bone mineral density of the femoral head,
which would reduce the possibility of the femoral head
collapse. In the present study, we applied the teriparatide
dosage for 20 μg/kg because most of the rodent models
reported the use of 5–200 (typically 40) μg/kg BW/day for
anabolic effects on skeletal repair. However, the clinical
dose for osteoporosis treatment was 20 μg per day for an
adult person. Animal models used supraphysiologic doses









0.55 ± 0.11 0.65 ± 0.11 −2.26 0.035
Bone Surface Area/
Bone Volume
22.42 ± 5.20 17.30 ± 4.78 2.46 0.023
Trabecular Thickness 0.09 ± 0.03 0.12 ± 0.03 −2.27 0.034
Trabecular Number 5.87 ± 0.48 5.39 ± 0.77 1.76 0.094
Trabecular Spacing 0.08 ± 0.02 0.07 ± 0.02 1.68 0.107
Trabecular Pattern
Factor
−0.47 ± 4.59 −4.20 ± 3.38 2.23 0.037
Cortical Wall Thickness 0.60 ± 0.12 0.54 ± 0.12 1.29 0.212
Bone Mineral
Density(mg/cc)
350.84 ± 79.93 447.49 ± 53.72 −3.431 0.003
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than that in human. This difference was considered to be
derived from species difference. However, it was possible
that more than osteoporosis dose might be necessary
to treat osteonecrosis in human. Moreover, as for the
osteonecrosis, the most suitable course of teriparatide
treatment is unclear. The therapy duration in our study
was four weeks, and we referred it to the bone union ani-
mal model. Alkhiary et al. applied the administration
of 30 μg/kg/day of teriparatide in rats with femoral closed
fracture showed an improvement in fracture healing since
the third week [30]. Nakazawa et al. gave daily subcutane-
ous injections of 10 μg/kg of recombinant human
PTH(1–34) [rhPTH(1–34)] over a 28-day period of frac-
ture healing. On day 14 after fracture, cartilage area in the
PTH-treated group was significantly increased [31]. In the
spine fusion animal model, Ni Ming et al. applied teripara-
tide 4 μg/kg per day and teriparatide 23 μg/kg per day
subcutaneous injections for 4 weeks (5 days per wk) after
the spine fusion surgery in the rat model. They found teri-
paratide at 23 μg/kg per day for 4 weeks showed anabolic
skeletal effects and significantly enhanced spinal fusion
rate in rats [32]. However, some researchers also conduct
the study with a follow up of 6–8 weeks. Longer course of
treatment needed to be studied in further research.
There were still some limits of our study: Firstly, in order
to save animals and for animal ethics, we designed the
study strictly with the expense of fewer animals. What’s
more, as the cost of the teriparatide was expensive, the
therapy duration was limited to 4 weeks. However, the loca-
tion specific analysis of osteonecrosis made up for the limi-
tation as double femoral heads were both evaluated in each
rat. Secondly, for human beings, the MRI has emerged as
the golden standard of the diagnosis of femoral head ne-
crosis. However, the most common diagnosis standard for
rats is histological examination. There are advantages of
micro CT with high resolution in evaluating the trabecu-
lae both qualitatively and quantitively, however, the early
staged osteonecrosis cann’t be displayed. Finally, the
underlying mechanism of teriparatide in osteonecrosis is
still unclear, which need to be clarified in further research.
Conclusions
In general, we present with a prospective randomized
animal study which may be the first study exploring the
potential effect of teriparatide in the treatment of steroid
induced osteonecrosis. Both the micro-CT analysis and
the histology results are promising, which is quite illu-
minating for justifying human studies.
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